Table 2 |
|||||||||
| Treatment Intensification Rates, Baseline Risk Factor Levels, Declines and Adjusted Differences During Follow-up - Study vs. Control Centers, Eligible Patients, by Priority Level | |||||||||
| Study (n = 4 sites) | Control (n = 4 sites) | ||||||||
| Priority | Number Eligible Patients | Intensified within 3 months | Baseline Mean Risk Factor Level† |
Unadjusted Risk Factor Decline‡ |
Number Eligible Patients | Intensified within 3 months | Baseline Mean Risk Factor Level† |
Unadjusted Risk Factor Decline‡ |
Adjusted Study-Control Risk Factor Differences (95% CI)¶ |
| 1: SBP ≥ 140 | 3,080 | 34.1€ | 153.2 | 13.6 | 2,905 | 30.6€ | 153.0 | 13.4 | 0.73 |
| (-1.40, 2.83) | |||||||||
| 2: LDL-c ≥ 130 | 2,431 | 28.0€ | 153.1 | 24.9 | 1,789 | 22.7€ | 153.9 | 23.8 | -2.63 |
| (-6.73, 1.48) | |||||||||
| 3: A1c ≥ 9% | 1,318 | 29.5 | 10.2 | 1.0 | 1,059 | 28.8 | 10.2 | 1.2 | -0.02 |
| (-0.36, 0.32) | |||||||||
| 4:SBP 130-139£ | 3,878 | 22.9 | 138.5 | 6.0 | 3,583 | 22.0 | 138.5 | 5.0 | -0.00 |
| (-1.25, 1.26) | |||||||||
| 5: LDL-c 100-129 | 4,876 | 20.5 | 111.4 | 10.1 | 3,526 | 19.1 | 111.3 | 8.9 | -0.83 |
| (-4.10, 2.44) | |||||||||
| 6. A1c 7-8.9% | 3,750 | 26.3 | 7.5 | 0 | 3,007 | 26.9 | 7.5 | 0 | 0.03 |
| (-0.10, 0.16) | |||||||||
† Based on the last value recorded before follow-up begins; i.e., the value that qualified patient for treatment intensification.
‡ Based on the first value recorded after 3 months follow-up; if no values recorded between 3 and 12 months follow-up, the latest value recorded during first 3 months follow-up was used. No values were available during follow-up for 3%, 10%, and 14% of blood pressure, A1c, and LDL-c tests, respectively.
¶ From repeated measures models using all available values during follow-up,with adjustment for age, gender, race-ethnicity, baseline risk factor value, number of medications for the risk factor at baseline, and days of follow-up at time of each measurement. Negative value indicates that the adjusted difference favored the study group group during follow-up.
€ p < 0.001 for study vs. control comparison.
£ Only patients with diabetes mellitus and/or chronic kidney disease were eligible for the target of SBP <130 mmHg.
Selby et al. BMC Health Services Research 2012 12:183 doi:10.1186/1472-6963-12-183
